Novo Nordisk A/S (NVO) Next Earnings Date & Options-Implied ±6.5% Move

$39.14 +2.22% NYSE • Public Delayed / 60s Snapshot

Novo Nordisk A/S (NVO) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.

ROARABLE C+ • HOLD / WATCH Cap $173.31B
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510066
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B+
Cash (12)Whales (10)SEC (16)Macro (16)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+3.6% Base Target
$67 Bull$41 Base$32 Bear
🔴 SUNDAY NIGHT PREP • 7:00 PM ET
WHALE OPTIONS TUG-OF-WAR:60% Call Buyers ($18.7M)
40% PutsMax Pain: $38.00
NEXT EST. REPORT: Upcoming Quarter (~28 DAYS)

Options-Implied Post-Earnings ±6.5% Bell Curve

±$2.54 Expected Swing
$36.60 (-6.5%)Spot $39.14$41.68 (+6.5%)
TRADER CROWD SENTIMENT POLL

Will NVO Beat & Rip or Miss Next Quarter?

Trailing EPS: $1.19 • YoY Revenue Growth: 2.2%

54% Bullish Beat46% Bearish Miss
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher + Guest Options & Prop-Trading Strategist

Whale Flow & Momentum Playbook: Trading NVO & AI Leaders Without Chasing Tops

  • ✓Exact institutional whale strikes & implied earnings range on NVO this week
  • ✓How active traders scale setups using funded prop-firm accounts instead of risking savings
  • ✓Free bonus: instant RQD Rating Flip alerts on all tracked momentum leaders
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
NVO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -5.26%📐 HORIZONTAL RANGE
2026-10-30O $39.61H $40.10L $39.54C $40.00VOL 15.25M
RES: $58.40SUP: $34.06SMA50: $41.23SMA200: $44.19
$53.19$48.76$44.33$39.90$35.48RES $58.40SUP $34.06$40.002026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NVO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
25.3%/yr Implied 5Y Growth

vs. +2.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NVO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →
LLY → NVO Confirmed Filing
Eli Lilly dual GIP/GLP-1 agonist tirzepatide (Zepbound/Mounjaro) demonstrated superior head-to-head weight loss vs. Novo Nordisk semaglutide (Wegovy) in SURMOUNT-5, intensifying PBM rebate competition.
NVO → ISRG Confirmed Filing
Intuitive Surgical explicitly disclosed in its Form 10-K that US bariatric surgery procedure volumes on da Vinci robotic systems slowed as patients trialed GLP-1 weight-loss drugs prior to surgery.
DHR → NVO Analyst Hypothesis
Novo Nordisk $6B+ annual API manufacturing expansions utilize downstream purification chromatography resins and single-use filtration consumables where Danaher Cytiva and Pall hold leading bioprocess share.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NVO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

NVO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is NVO's next earnings date?

Based on SEC filing cadence, Novo Nordisk A/S (NVO)'s next quarterly earnings window is estimated around Upcoming Quarter.

How much is NVO stock expected to move on earnings?

Options markets currently imply a ±6.5% post-earnings move for NVO, projecting a trading range between $36.6 and $41.68.